Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide

Viral infections, particularly cytomegalovirus (CMV), contribute significantly to morbidity and mortality in recipients of allogeneic hematopoietic stem cell transplantation (HSCT) [1]. Post-transplantation cyclophosphamide (PTCy)-based platforms for graft-versus-host disease (GVHD) prophylaxis are increasingly used in HSCT, but they may be associated with a higher risk of CMV reactivation [2,3], potentially increasing morbidity and nonrelapse mortality (NRM). Studies of CMV infection in the context of PTCy have focused on comparisons with calcineurin inhibitors or have contrasted HSCT from haploidentical (Haplo) donors with HSCT from matched sibling donors (MSDs) and/or unrelated donors (MUDs) [2 –4].

Source: Biology of Blood and Marrow Transplantation - February 5, 2024 Category: Hematology Authors: Pedro Chor ão, Marta Henriques, Marta Villalba, Juan Montoro, Aitana Balaguer-Roselló, Eva María González, María Dolores Gómez, Inés Gómez, Pilar Solves, Marta Santiago, Pedro Asensi, Brais Lamas, Ana Bataller, Pablo Granados, Juan Eiris, David Ma Tags: Full Length Article Source Type: research